Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer

Lucy J. Schmidt; Donald J. Tindall

doi:10.1016/j.jsbmb.2010.09.003

Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer

Lucy J. Schmidt, Donald J. Tindall

Urology

Research output: Contribution to journal › Review article › peer-review

36 Scopus citations

Abstract

Steroid 5 alpha-reductase inhibitors (5ARIs) have been approved for use clinically in treatment of benign prostate hyperplasia (BPH) and accompanying lower urinary tract symptoms (LUTS) and have also been evaluated in clinical trials for prevention and treatment of prostate cancer. There are currently two steroidal inhibitors in use, finasteride and dutasteride, both with distinct pharmacokinetic properties. This review will examine the evidence presented by various studies supporting the use of these steroidal inhibitors in the prevention and treatment of prostate disease. Article from the Special issue on Targeted Inhibitors.

Original language	English (US)
Pages (from-to)	32-38
Number of pages	7
Journal	Journal of Steroid Biochemistry and Molecular Biology
Volume	125
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jsbmb.2010.09.003
State	Published - May 1 2011

Keywords

5 Alpha-reductase inhibition
Chemoprevention
Prostate disease

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Biochemistry
Molecular Medicine
Molecular Biology
Endocrinology
Clinical Biochemistry
Cell Biology

Access to Document

10.1016/j.jsbmb.2010.09.003

Cite this

@article{e325f9f155744e6f94a1fc1ae331d26c,

title = "Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer",

abstract = "Steroid 5 alpha-reductase inhibitors (5ARIs) have been approved for use clinically in treatment of benign prostate hyperplasia (BPH) and accompanying lower urinary tract symptoms (LUTS) and have also been evaluated in clinical trials for prevention and treatment of prostate cancer. There are currently two steroidal inhibitors in use, finasteride and dutasteride, both with distinct pharmacokinetic properties. This review will examine the evidence presented by various studies supporting the use of these steroidal inhibitors in the prevention and treatment of prostate disease. Article from the Special issue on Targeted Inhibitors.",

keywords = "5 Alpha-reductase inhibition, Chemoprevention, Prostate disease",

author = "Schmidt, {Lucy J.} and Tindall, {Donald J.}",

year = "2011",

month = may,

day = "1",

doi = "10.1016/j.jsbmb.2010.09.003",

language = "English (US)",

volume = "125",

pages = "32--38",

journal = "Journal of Steroid Biochemistry and Molecular Biology",

issn = "0960-0760",

publisher = "Elsevier Limited",

number = "1-2",

}

TY - JOUR

T1 - Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer

AU - Schmidt, Lucy J.

AU - Tindall, Donald J.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Steroid 5 alpha-reductase inhibitors (5ARIs) have been approved for use clinically in treatment of benign prostate hyperplasia (BPH) and accompanying lower urinary tract symptoms (LUTS) and have also been evaluated in clinical trials for prevention and treatment of prostate cancer. There are currently two steroidal inhibitors in use, finasteride and dutasteride, both with distinct pharmacokinetic properties. This review will examine the evidence presented by various studies supporting the use of these steroidal inhibitors in the prevention and treatment of prostate disease. Article from the Special issue on Targeted Inhibitors.

AB - Steroid 5 alpha-reductase inhibitors (5ARIs) have been approved for use clinically in treatment of benign prostate hyperplasia (BPH) and accompanying lower urinary tract symptoms (LUTS) and have also been evaluated in clinical trials for prevention and treatment of prostate cancer. There are currently two steroidal inhibitors in use, finasteride and dutasteride, both with distinct pharmacokinetic properties. This review will examine the evidence presented by various studies supporting the use of these steroidal inhibitors in the prevention and treatment of prostate disease. Article from the Special issue on Targeted Inhibitors.

KW - 5 Alpha-reductase inhibition

KW - Chemoprevention

KW - Prostate disease

UR - http://www.scopus.com/inward/record.url?scp=79957696618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957696618&partnerID=8YFLogxK

U2 - 10.1016/j.jsbmb.2010.09.003

DO - 10.1016/j.jsbmb.2010.09.003

M3 - Review article

C2 - 20883781

AN - SCOPUS:79957696618

SN - 0960-0760

VL - 125

SP - 32

EP - 38

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

IS - 1-2

ER -

Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this